Company intelligence / Profile preview
Ferring Pharmaceuticals
- Ownership
- Private
- Employees
- ~7000
- Development stage
- Other
Overview
Ferring has a broad commercial portfolio with multiple approved products in reproductive medicine, maternal health, gastroenterology, urology, and emerging areas like the human microbiome. Recent clinical successes include FDA approvals for Adstiladrin® (nadofaragene firadenovec-vncg) for high-risk BCG-unresponsive NMIBC and Rebyota® for recurrent C. difficile infection. The company continues to invest heavily in R&D (~15% of revenue), with ongoing late-stage programs in gene therapy and live biotherapeutics.
- Therapeutic areas
- Women's HealthOncologyGastroenterology
- Modalities
- Small moleculesHormones/peptides (e.g., oxytocin, vasopressin)AAV-based gene therapyFusion proteinsMicrobiome-based live biotherapeutics
- Industry
- Biotech
Drug pipeline
49 assets48 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ferring Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ferring Pharmaceuticals.